Why Peptide Brands Can't Get Payment Processors (And How To Actually Get One)

Payment processors and the card networks behind them (Visa, Mastercard, AmEx, Discover) classify merchants by MCC code and by category-level risk. Peptide brands are flagged on three independent risk dimensions simultaneously, which is what makes them one of the hardest categories to underwrite anywhere.

The first dimension is product-category risk. Peptides sit adjacent to nutraceuticals, supplements, and pharmaceuticals — categories with documented histories of consumer complaints, regulatory action, and chargeback elevation. The second dimension is fulfillment-pattern risk. Peptide brands typically run online-only models, ship internationally, use international suppliers, and operate with margins that make refund disputes common. The third dimension is regulatory exposure. RUO (research-use-only) products live in a grey zone of FDA and equivalent international oversight. A processor underwriting a peptide brand is, in effect, taking on potential exposure to future regulatory action that might affect the brand or the category as a whole.

From the processor's perspective, even a perfectly compliant peptide brand carries a level of category-level reputational and financial risk that mainstream brands do not. Processors are not making a judgment about you specifically when they decline. They are making a portfolio-level decision about peptide-vertical exposure. Understanding this changes how you approach the conversation with every processor you ever pitch.

Stripe, PayPal, and Square are the three processors every founder thinks of first because they are the easiest to integrate and have the lowest published rates. They are also the three processors most likely to terminate a peptide merchant — often after months of seemingly successful operation. We have seen this pattern dozens of times.

What happens with Stripe is consistent: the brand integrates Stripe via Shopify or a custom checkout. Sales work fine for weeks or months. Then a routine internal review flags the merchant as out of policy. Stripe sends a notice, freezes the account, holds reserves for 90–120 days, and refuses further processing. The brand is left with no payment infrastructure, frozen working capital, and no recourse. PayPal operates the same way but typically moves faster and with even less explanation. Square is the most aggressive of the three — many peptide brands have been terminated within days of their first transaction.

The lesson every peptide brand eventually learns: mainstream processors are not a starting point you can graduate from. They are an unstable foundation that will collapse at the worst possible moment. The brands that build right do not use them at all. They start with high-risk processors from day one.

There is a small but real ecosystem of payment processors and gateways that underwrite peptide brands. Names you will encounter include Easy Pay Direct, NMI (Network Merchants Inc.), Authorize.net (via certain gateway partners), Durango Merchant Services, eMerchantBroker, Soar Payments, PaymentCloud, Corepay, and a handful of regional specialists. None of these are household names. That is the point — high-risk processing is a relationship business that does not advertise to consumers.

These processors operate differently from mainstream ones in three ways that matter. First, their published rates are higher. Expect interchange-plus pricing with markup that puts peptide brand effective rates between 3.5% and 6% depending on the processor and the relationship. Second, their underwriting requirements are heavier. Expect to provide formation documents, three months of bank statements, identification for owners and officers, processing history if you have any, projected volume, supplier documentation, and a detailed business description. Third, their relationships are more durable when set up correctly. A high-risk processor that has underwritten you knows what business you run. They are far less likely to terminate you for being what they already understood you to be.

The trade-off is real. You pay more in fees, you do more work to onboard, and you operate inside tighter chargeback rules. In exchange you get payment processing that does not vanish overnight. For a peptide brand, that exchange is the only sustainable model.

Every processor, mainstream and high-risk alike, monitors chargeback rate as their primary in-life risk metric. The threshold to watch is 1%. Most processors begin internal escalation when chargeback rate crosses 0.65–0.75%. Most will terminate or impose reserves when chargeback rate crosses 1% for two consecutive months. Card networks themselves impose punitive programs (Visa Dispute Monitoring Program, Mastercard's Excessive Chargeback Program) when merchant-level chargeback rates stay elevated.

Peptide brands face structural chargeback risk for reasons most generalist DTC brands never encounter. Customers occasionally dispute on receipt because they did not understand what they ordered. Refund disputes sometimes get escalated by the customer to the issuing bank rather than worked out through the merchant. Suspicious transactions on stolen cards target peptide brands because the products are easy to resell. Some customers use chargebacks tactically when they regret a purchase. All of these patterns conspire to make peptide chargeback rates harder to control than equivalent supplement brands.

The single most effective intervention is operational rather than technical. Brands that invest in clear product expectations on the PDP, proactive shipping notifications, fast and easy refund flows, and chargeback-prevention services (Verifi, Ethoca) keep chargeback rates well below the danger zone. Brands that treat chargebacks as someone else's problem end up unbanked. We make chargeback discipline a non-negotiable part of every operations workflow we build.

A common question from new peptide brand founders is whether they can start with a workaround — crypto-only checkout, manual invoicing, ACH, gift cards, or some other non-card payment method — until they get processor approval. The honest answer is that none of these workarounds scale and most of them actively damage the brand's ability to get a real processor later.

Crypto-only checkout converts at a fraction of card checkout rates. Most peptide customers in the US, UK, AU, and UAE will not buy from a brand that only accepts crypto. Manual invoicing introduces fraud risk and friction that destroys conversion. Gift card systems and reseller workarounds violate the terms of service of the platforms that issue them and frequently lead to platform-level bans on top of payment bans. ACH is too slow and too unfamiliar for a typical consumer-facing checkout flow.

More importantly, a brand that operates without a real processor for its first six months looks like a high-risk underwriting candidate to every processor it eventually approaches. There is no processing history to evaluate. There is no chargeback record. There is no banking pattern that demonstrates the brand operates within norms. Starting without a real processor materially extends the time and difficulty of eventually getting one. The right move is to set up high-risk processing from day one, even if it costs more, even if approval takes longer, even if launching is delayed by two months as a result.

Every mature peptide brand in our portfolio runs at least two payment processors in parallel — and most run three. This is not a luxury. It is a continuity strategy. When one processor freezes or terminates, the second processor keeps revenue flowing while the third gets onboarded as the new backup. Brands that run single-processor setups face existential risk every time the underwriting team at their processor does a routine portfolio review.

The architecture we typically implement uses a primary processor that handles the bulk of transactions, a secondary processor that handles cards declined by the primary or operates a parallel cart at the checkout level, and a contingency processor that is fully onboarded but inactive — waiting for the day it is needed. The primary and secondary should ideally be at different acquirers and through different gateways so that an acquirer-level decision does not affect both at once.

Multi-processor strategies require checkout infrastructure that can dynamically route transactions based on processor health. Most Shopify-native checkouts cannot do this well. Custom checkouts and headless commerce platforms handle it cleanly. This is one of the reasons many peptide brands move off vanilla Shopify Payments and onto more flexible checkout architectures as they scale.

International peptide brands face an even more fragmented processor landscape than US brands. UK brands typically work through gateways like Opayo (formerly Sage Pay), Worldpay's high-risk division, and select international high-risk specialists. Australian brands use eWAY, Tyro, and international high-risk routing. UAE brands rely on Network International, Telr, Magnati, and increasingly Stripe for merchants that pass UAE-specific qualification. Each market has its own card networks, regulatory frameworks, and processor underwriting norms.

Brands operating across multiple markets typically run different processors per market rather than a single global processor. The economics, fraud patterns, and chargeback dynamics in each market are different enough that processor selection should be local. A US-optimized processor stack will not serve UAE customers efficiently and vice versa.

Cross-border processing introduces additional complexity around FX, settlement timing, regulatory reporting, and tax handling. Brands operating cross-border should architect for it from day one rather than try to retrofit later. The cost of unwinding a single-processor cross-border setup at scale is meaningfully higher than the cost of building it correctly initially.

The actual mechanics of getting approved by a high-risk processor are unglamorous but reliable. You prepare a complete underwriting package: formation documents, identification, three months of business banking statements, prior processing statements if any, supplier and fulfillment documentation, projected monthly volume, average transaction size, geographic mix, refund and chargeback policy, and a clear written description of what your business does and how. You submit the package and wait. Approvals take between five and twenty business days for established processors. Pre-approval phone calls are common and matter.

What gets a brand approved faster: clean banking, demonstrable knowledge of the vertical, conservative initial volume projections, clear documentation of compliance practices, and (often) an introduction from someone the processor already trusts. What slows approval down: gaps in documentation, inconsistent statements, prior processor terminations on record, and any signals that the founder does not understand the vertical they are operating in.

An agency or operator with established processor relationships can compress this timeline meaningfully. We routinely shepherd new peptide brands through their first high-risk processor onboarding in under ten business days, which is roughly half the time a founder doing it alone usually takes.

Payment infrastructure is one of the non-negotiable workstreams in every full-stack engagement we run. For new brands, that means structuring the processor stack before launch, making the introductions to processors that fit the brand's profile, supporting the underwriting package, and architecting the checkout to support multi-processor routing from day one. For established brands, that means auditing the current processor stack, identifying single-point-of-failure risk, adding redundancy where it is missing, and implementing chargeback discipline that keeps the existing processors stable.

We do not operate as a processor ourselves. We operate as the team that knows the landscape, the language, and the people. That distinction matters. Processor relationships in this vertical are personal — built across years and shared across operators who trust each other. A new brand benefits enormously from being introduced by someone whose track record at processors is already known. That alone often gets a brand approved that would have been declined on a cold application.

If you are setting up a peptide brand for the first time, or your current processor has frozen you, or you simply want to add redundancy to a working setup, this is the kind of work we handle inside every engagement. Reach out and we will walk you through what your specific stack should look like.

Marketing is what most founders want to talk about first. We understand the instinct. Marketing is the engine. But if the foundation underneath the engine is unstable, the engine produces output that cannot be cashed. Payments come before marketing. Every brand we have helped scale into eight-figure revenue had its payment infrastructure right before its marketing began compounding. The ones that did it in the other order spent years recovering from preventable processor crises.

Get the processor stack right first. The marketing wins are only worth what your checkout can actually capture.